852402-71-2

Basic information

• Product Name: 2-Quinolinecarboxylicacid,7-methoxy-(9CI)
• Synonyms: 2-Quinolinecarboxylicacid,7-methoxy-(9CI)
• CAS NO: 852402-71-2
• Molecular Formula: C₁₁H₉NO₃
• Molecular Weight: 203.19406
• Product Categories: QUINOLINE
• Mol File: 852402-71-2.mol

Chemical Properties

• Melting Point: 154 °C
• Boiling Point: 385.4±27.0 °C(Predicted)
• Appearance: /
• Density: 1.325±0.06 g/cm3(Predicted)
• PKA: 1.14±0.30(Predicted)
• CAS DataBase Reference: 2-Quinolinecarboxylicacid,7-methoxy-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Quinolinecarboxylicacid,7-methoxy-(9CI)(852402-71-2)
• EPA Substance Registry System: 2-Quinolinecarboxylicacid,7-methoxy-(9CI)(852402-71-2)

Safety Data

• Hazardous Substances Data: 852402-71-2(Hazardous Substances Data)

Upstream product

• 4964-76-5 7-methoxyquinoline 
• 98-88-4 benzoyl chloride 
• 862249-71-6 7-methoxyquinoline-2-carbaldehyde 
• 19490-87-0 7-methoxy-2-methylquinoline 
• 536-90-3 m-Anisidine 
• 90-04-0 2-methoxy-phenylamine 
• 22996-21-0 4-methoxy-2-nitro-benzaldehyde 
• 59236-36-1 2-amino-4-methoxybenzaldehyde 
• 57-60-3 piruvate 

Downstream Products

• 852402-75-6 (S)-7-methoxyquinoline-2-carboxylic acid (1-phenylethyl)amide 
• 852402-96-1 (4aS,1'S)-9-methoxy-3-(1-phenylethyl)-2,3,4,4a,5,6-hexahydropyrazino[1,2-a]quinolin-1-one 
• 852402-91-6 (4aR,1'S)-9-methoxy-3-(1-phenylethyl)-2,3,4,4a,5,6-hexahydropyrazino[1,2-a]quinolin-1-one 
• 852403-06-6 (4aS,1'S)-9-methoxy-3-(1-phenylethyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoline 
• 852403-01-1 (4aR,1'S)-9-methoxy-3-(1-phenylethyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoline 
• 852402-80-3 (2R,3'S)-7-methoxy-1,2,3,4-tetrahydroquinoline-2-carboxylic acid (1-phenylethyl)amide 
• 852402-85-8 (2S,3'S)-7-methoxy-1,2,3,4-tetrahydroquinoline-2-carboxylic acid (1-phenylethyl)amide 

Relevant articles and documents

Repurposing an Aldolase for the Chemoenzymatic Synthesis of Substituted Quinolines

Quinoline derivatives are important natural products and pharmaceuticals, but their synthesis can be challenging due to poor yields, harsh reaction conditions, and instability of starting materials. Here we report the chemoenzymatic synthesis of quinaldic acids under mild conditions using an aldolase, trans-o-hydroxybenzylidenepyruvate hydratase-aldolase (NahE, or HBPA). A series of 2-aminobenzaldehydes derived from reduction of the corresponding nitro analogue were reacted with pyruvate in the presence of NahE to give substituted quinolines in up to 93% isolated yield. This reaction differs from the aldol condensation catalyzed by NahE in vivo, instead resembling the heterocycle formation catalyzed by its homologue, dihydrodipicolinate synthase.

HCV NS5A replication complex inhibitors. Part 4.1 optimization for genotype 1a replicon inhibitory activity

A series of symmetrical E-stilbene prolinamides that originated from the library-synthesized lead 3 was studied with respect to HCV genotype 1a (G-1a) and genotype 1b (G-1b) replicon inhibition and selectivity against BVDV and cytotoxicity. SAR emerging f

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.